Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > TIGIT > EP-131

TIGIT : CD155 [Biotinylated] Inhibitor Screening ELISA Kit

For research use only.

Order Now

EP131-C01High-bind Plate1plate
EP131-C02Human TIGIT10μg
EP131-C03Biotinylated Human CD15535μg
EP131-C04Anti-TIGIT Neutralizing Antibody20μg
EP131-C06Coating Buffer12mL
EP131-C0710xWashing Buffer 50mL
EP131-C08Blocking Buffer50mL
EP131-C09Substrate Solution12mL
EP131-C10Stop Solution7mL
  • Background
    CD155 and ITIM domains (TIGIT) is a novel type of immune checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression and promotes the proliferative and migratory abilities of tumor cells via various pathways. TIGIT, an inhibitory receptor, is mainly expressed on natural killer (NK), CD8+ T, CD4+ T and T regulatory (Treg) cells. CD155 transmits immune signals via interacting with the inhibitory checkpoint receptor TIGIT, thereby inhibiting the function of T and NK cells.CD155 is highly expressed on the surface of DC cells. When TIGIT on T cells binds to CD155 on DC cells, CD155 will send signals to DC cells to up-regulate the secretion of IL-10 and down-regulate the secretion of IL-12, thereby weakening the immune response mediated by DC cells. DC cells are important antigen-presenting cells in the body, and reduced DC cell activity in turn reduces T cell activity.
  • Application

    This kit is developed for screening for inhibitors of human TIGIT binding to human CD155.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new TIGIT pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human CD155 to immobilized human TIGIT in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated CD155 protein, a human TIGIT protein, an anti-TIGIT neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human TIGIT.

    b) Add your molecule of interest to the tests.

    c) Add human CD155-Biotin to bind the coated human TIGIT.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to TIGIT: CD155 binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to Ds document for the assay protocol.

Serial dilutions of Anti-TIGIT Neutralizing antibody (Catalog # EP131-C04) (1:1 serial dilution, from 5 μg/mL to 0.01μg/mL) was added into TIGIT: Biotinylated CD155 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:38 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message